Výsledky vyhledávání - "Fiona G. McKissock"

The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent

Autor: Jennifer Bré, Alison L. Dickson, Oliver J. Read, Ying Zhang, Fiona G. McKissock, Peter Mullen, Peijun Tang, Greice M. Zickuhr, Clarissa M. Czekster, David J. Harrison

Publikováno v: Cancer Chemotherapy and Pharmacology. 91:401-412

Introduction Fluoropyrimidines, principally 5-fluorouracil (5-FU), remain a key component of chemotherapy regimens for multiple cancer types, in particular colorectal and other gastrointestinal malignancies. To overcome key limitations and pharmacolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d806fb950ffd20e09ec9f1c3ba63c442
https://doi.org/10.1007/s00280-023-04528-5

Zobrazit plný text záznamu

Abstract 1848: NUC-3373 induces ER stress and the release of damage associated molecular patterns in colorectal cancer cells

Autor: Fiona G. McKissock, David J. Harrison, Oliver J. Read

Publikováno v: Cancer Research. 80:1848-1848

Background: NUC-3373 is a ProTide transformation of fluorodeoxyuridine monophosphate (FUDR-MP), the active anti-cancer metabolite of 5-fluorouracil (5-FU). NUC-3373 can overcome key cancer resistance mechanisms and the rapid degradation known to impa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::29a89b8f491d3f6858584bd2aee8b2c9
https://doi.org/10.1158/1538-7445.am2020-1848

Zobrazit plný text záznamu

Abstract C059: Inhibition of thymidylate synthase by the ProTide NUC-3373: in vitro analysis and clinical validation

Autor: Fiona G. McKissock, Jordan Berlin, T.R. Jeffry Evans, Sarah P. Blagden, Michelle Myers, Lisa Jane Rodgers, David J. Harrison, Kristen K. Ciombor, Francesca Aroldi, Janet Graham

Publikováno v: Molecular Cancer Therapeutics. 18:C059-C059

Background: Although 5-FU-based regimens such as FOLFOX and FOLFIRI remain the standard of care for treatment of patients with colorectal cancer (CRC), their clinical utility is limited by resistance mechanisms and the production of toxic by-products

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e705dfdbb5b8413fce006f15acb400b
https://doi.org/10.1158/1535-7163.targ-19-c059

Zobrazit plný text záznamu

Abstract 2082: NUC 3373 induces a cytoplasmic translocation of thymidylate synthase in colorectal carcinoma cell lines

Autor: Fiona G. McKissock, In Hwa Um, Peter Mullen, David J. Harrison

Publikováno v: Cancer Research. 79:2082-2082

BACKGROUND: Although 5-fluorouracil-based (5-FU) chemotherapies remain the cornerstone of combination therapies for colorectal cancer (CRC), their clinical utility is limited by key cancer resistance mechanisms associated with breakdown, transport, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f33ed7828fc95ce99755ee4252ffedae
https://doi.org/10.1158/1538-7445.am2019-2082

Zobrazit plný text záznamu

Abstract 2081: NUC 3373 induces endoplasmic reticulum stress in colorectal cancer cells

Autor: Fiona G. McKissock, Asmithaa Prabhakaran, Peter Mullen, David J. Harrison

Publikováno v: Cancer Research. 79:2081-2081

Background Although 5-fluorouracil-based (5-FU) chemotherapies remain the cornerstone of combination therapies for colorectal cancer (CRC), their clinical utility is limited by key cancer resistance mechanisms associated with breakdown, transport, an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c03a3ec37be80a9a94ec91e400fa0523
https://doi.org/10.1158/1538-7445.am2019-2081

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání